DeviceVM, a San Jose, Calif.-based developer of rapid-start computing technologies, has raised $10 million in Series B funding. DFJ Dragon led the deal, and was joined by Sumitomo's venture arm (Presidio), HTC Founders Cher Wang and Chen Wen Chi and WR Hembrecht Ventures. The company had raised a $10.5 million Series A round just two […]
DARA Biosciences Inc. has agreed to go public via a reverse merger with Point Therapeutics Inc. (Nasdaq: POTP), following which DARA shareholders would hold 96.4% of Point's outstanding shares. The merged company will retain the DARA Biosciences name. DARA is a Raleigh, N.C.-based drug company that has raised just over $10 million in VC funding […]
Behrman Capital is targeting $1 billion for its fourth fund, according to a regulatory filing. The New York-based buyout firm previously raised $1.2 billion for its third fund in 2001, and already has secured more than $137 million for its new effort. www.behrmancap.com
Warburg Pincus has held a $9 billion first close for its tenth fund, according to LBO Wire. The New York-based firm is targeting $12 billion, and began fundraising this past March. www.warburgpincus.com
Tamir Fishman Ventures has agreed to become Draper Fisher Jurvetson's network partner in Israel, and to re-brand as DFJ Tamir Fishman Ventures. www.dfj.com www.tfventures.com
Apax Partners has added three associates to its Paris-based team. They are: Damien de Bettignies, formerly with McKinsey & Co., who will focus on tech and telecom; Julien Gauthier, previously with Barclays' Leverage Finance team, who will focus on business and financial services; and Marc Philouze, previously with Pfizer, who will focus on healthcare. www.apax.com
Kurt Larson has decided to leave Cerberus, in order to head up private equity activities for Moelis & Co., according to Deal Journal. Moelis & Co. is the new boutique formed by former UBS I-banking head Ken Moelis.
Darren Redmayne has agreed to join mid-market I-bank Lincoln International as a managing director, effective January 2008. He will be charged with founding Lincoln's London office, and previously was co-founder and head of Close Brothers' financial sponsors group. www.lincolninternational.com
Ablynx NV, a Belgium-based drug company focused on a novel class of antibody-derived therapeutic proteins, said that it plans to list on Euronext Brussels later this year, subject to market conditions. J.P. Morgan Securities and KBC Securities will serve as co-lead underwriters. Ablynx has raised
ICAP PLC (LSE: IAP), an inter-dealer broker, has agreed to acquire Traiana Inc., a New York